OasisLMS

The treatment of endometrial cancer has greatly changed in the last years and molecular profiling is a mainstay to define patients’ prognosis and treatment both in the adjuvant to the metastatic setting of disease. In this ideal patient journey, we will report what are the new standard treatments in the adjuvant and metastatic setting of endometrial cancer according to the molecular profile and in addition, we will review the new treatment opportunities that will come in the next future and the ongoing clinical trials.

Chairs	Roberta Mazzeo (Spain)   Hannah Simonds (South Africa)
Case Presentation	Sathya Manoharan (Australia)
New Approaches for Systemic Adjuvant Treatment	Yvette Drew (Canada)
Is There Still a Role for Adjuvant Radiation?	David Gaffney (United States of America)
Q&A and Discussion (ID 97)
OP007 - LENVATINIB PLUS PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN PARTICIPANTS WITH ADVANCED ENDOMETRIAL CANCER: 5-YEAR OUTCOMES FROM STUDY 309/KEYNOTE-775 Abstract	Vicky Makker (United States of America)
Metastatic – Immunotherapy for All?	Ramez Eskander (United States of America)
Novel Therapies and Ongoing Clinical Trials, ADCs: How Will We Choose When There Are So Many Options?	Domenica Lorusso (Italy)
Q&A and Discussion